CA2855941A1 - Pharmaceutical preparations of human rpe cells and uses thereof - Google Patents

Pharmaceutical preparations of human rpe cells and uses thereof Download PDF

Info

Publication number
CA2855941A1
CA2855941A1 CA2855941A CA2855941A CA2855941A1 CA 2855941 A1 CA2855941 A1 CA 2855941A1 CA 2855941 A CA2855941 A CA 2855941A CA 2855941 A CA2855941 A CA 2855941A CA 2855941 A1 CA2855941 A1 CA 2855941A1
Authority
CA
Canada
Prior art keywords
cells
cell
rpe
rpe cells
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2855941A
Other languages
English (en)
French (fr)
Inventor
Roger GAY
Irina Klimanskaya
Robert Lanza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Advanced Cell Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47470610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2855941(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Advanced Cell Technology Inc filed Critical Advanced Cell Technology Inc
Priority to CA3178098A priority Critical patent/CA3178098A1/en
Publication of CA2855941A1 publication Critical patent/CA2855941A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mechanical Engineering (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
CA2855941A 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof Pending CA2855941A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3178098A CA3178098A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161559521P 2011-11-14 2011-11-14
US61/559,521 2011-11-14
US201261589741P 2012-01-23 2012-01-23
US61/589,741 2012-01-23
US201261724047P 2012-11-08 2012-11-08
US61/724,047 2012-11-08
PCT/US2012/065091 WO2013074681A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3178098A Division CA3178098A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Publications (1)

Publication Number Publication Date
CA2855941A1 true CA2855941A1 (en) 2013-05-23

Family

ID=47470610

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2855941A Pending CA2855941A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof
CA3178098A Pending CA3178098A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3178098A Pending CA3178098A1 (en) 2011-11-14 2012-11-14 Pharmaceutical preparations of human rpe cells and uses thereof

Country Status (23)

Country Link
US (4) US20130195806A1 (https=)
EP (2) EP3563860A1 (https=)
JP (7) JP6506023B2 (https=)
KR (1) KR102054904B1 (https=)
CN (2) CN104080464A (https=)
AU (5) AU2012340020A1 (https=)
CA (2) CA2855941A1 (https=)
CY (1) CY1121819T1 (https=)
DK (1) DK2780022T4 (https=)
ES (1) ES2734453T3 (https=)
FI (1) FI2780022T4 (https=)
GB (1) GB2496969A (https=)
HK (1) HK1202456A1 (https=)
HR (1) HRP20191110T1 (https=)
HU (1) HUE044778T2 (https=)
IL (5) IL320536A (https=)
LT (1) LT2780022T (https=)
PL (1) PL2780022T3 (https=)
PT (1) PT2780022T (https=)
RS (1) RS59050B1 (https=)
SI (1) SI2780022T1 (https=)
TW (5) TWI719277B (https=)
WO (1) WO2013074681A1 (https=)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0507074A (pt) 2004-01-23 2007-06-19 Advanced Cell Tech Inc modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
IL292561A (en) 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
EP2596119B8 (en) 2010-07-23 2021-06-02 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
JP6329072B2 (ja) 2011-09-26 2018-05-23 キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 細胞外核酸の安定化および単離
CN103827303B (zh) 2011-09-26 2021-10-22 普瑞阿那利提克斯有限公司 细胞外核酸的稳定化和分离
TWI719277B (zh) * 2011-11-14 2021-02-21 美商安斯泰來再生醫藥協會 人類rpe細胞之醫藥組合物及其用途
CN104755628B (zh) 2012-09-25 2019-03-01 凯杰有限公司 生物样品的稳定化
EP2951290B1 (en) 2013-02-01 2017-11-29 The United States of America, as represented by The Secretary, Department of Health and Human Services Method for generating retinal pigment epithelium (rpe) cells from induced pluripotent stem cells (ipscs)
JP6407248B2 (ja) 2013-03-18 2018-10-17 キアゲン ゲーエムベーハー 細胞外核酸の安定化および単離
US11525155B2 (en) 2013-03-18 2022-12-13 Qiagen Gmbh Stabilisation of biological samples
BR112016011096A2 (pt) 2013-11-27 2017-09-19 Kyoto Prefectural Public Univ Corp Aplicação de laminina à cultura de célula endotelial da córnea
CA2933083A1 (en) 2013-12-11 2015-06-18 Pfizer Limited Method for producing retinal pigment epithelial cells
CN106102766A (zh) * 2014-01-22 2016-11-09 皮埃尔与玛丽·居里大学 - 巴黎第六大学 用于治疗视网膜炎症的试剂
EP2898896A1 (en) * 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents for use in the treatment of retinal inflammation
JP6664332B2 (ja) * 2014-03-18 2020-03-13 キアゲン ゲーエムベーハー 細胞外核酸の安定化および単離
WO2015175504A1 (en) * 2014-05-12 2015-11-19 The Johns Hopkins University Differentiation of human pluripotent stem cells into retinal pigment epithelium using hif1 inhibitors
US10457915B2 (en) 2014-05-15 2019-10-29 International Stem Cell Corporation Chemical differentiation of pluripotentstem cells into retinal epithelial cells
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US20160095307A1 (en) 2014-10-07 2016-04-07 NuTech Medical, Inc. Method and composition for hypothermic storage of placental tissue
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CN121891508A (zh) * 2014-10-31 2026-04-21 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
EP3213761B1 (en) * 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
WO2016097183A1 (en) * 2014-12-18 2016-06-23 Universite Pierre Et Marie Curie (Paris 6) Transgenic rpe cells overexpressing otx2 for the treatment of retinal degeneration
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
CN114533761A (zh) * 2014-12-30 2022-05-27 细胞治疗神经科学有限公司 治疗视网膜疾病的方法
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
ES2980659T3 (es) * 2015-03-23 2024-10-02 Astellas Inst For Regenerative Medicine Ensayos mejorados de potencia de células de epitelio pigmentario retiniano (EPR) humano y progenitores de fotorreceptores
CN105013010B (zh) * 2015-07-07 2018-01-12 中山大学中山眼科中心 一种辅助iPS‑RPE移植的层粘连蛋白膜
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
SG10201913250SA (en) 2015-08-18 2020-03-30 Astellas Inst For Regenerative Medicine Clinical formulations
KR20260003355A (ko) * 2015-09-08 2026-01-06 후지필름 셀룰러 다이내믹스, 인코포레이티드 줄기 세포에서 유래된 망막색소상피의 macs 기반 정제
EP3377645B1 (en) 2015-11-20 2023-10-04 Qiagen GmbH Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
CN106420809B (zh) * 2016-08-31 2017-08-08 浙江济民制药股份有限公司 一种眼科手术灌注液
WO2018111981A1 (en) * 2016-12-13 2018-06-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US11076984B2 (en) * 2017-03-13 2021-08-03 Gyroscope Therapeutics Limited Method of performing subretinal drainage and agent delivery
EP3595687A1 (en) * 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
CA3061900A1 (en) * 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agriculturaand Mechanical College Compositions and methods for treating ocular pathologies
GB201721615D0 (en) 2017-12-21 2018-02-07 Koninklijke Nederlandse Akademie Van Wetenschappen Immune cell organoid co-cultures
BR112020013238A2 (pt) * 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
US12029683B2 (en) 2018-02-22 2024-07-09 Alcon Inc. Ocular implant and delivery system
MX2020009152A (es) * 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
AU2019385332B2 (en) * 2018-11-19 2025-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue replacement implant and its use
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
US12454701B2 (en) * 2018-12-05 2025-10-28 Abeona Therapeutics Inc. Recombinant adeno-associated viral vector for gene delivery
JP7701879B2 (ja) * 2019-05-28 2025-07-02 エフ． ホフマン－ラ ロシュ アーゲー 単球前駆細胞を生成するための方法
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
KR102198942B1 (ko) * 2019-07-02 2021-01-05 의료법인 성광의료재단 Pedf를 발현하거나 모세포에 비하여 pedf를 과발현하도록 유전적으로 조작된 중간엽 줄기세포
EP4013297A4 (en) 2019-08-16 2023-12-13 Poltorak Technologies, LLC DEVICE AND METHOD FOR MEDICAL DIAGNOSTICS
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021086911A1 (en) 2019-10-30 2021-05-06 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells
US12570955B2 (en) 2019-11-22 2026-03-10 Sigilon Therapeutics, Inc. Monoclonal cell lines expressing an exogenous substance and uses thereof
CA3167649A1 (en) 2020-01-21 2021-07-29 Takeda Pharmaceutical Company Limited Compositions and methods of cryopreserving cells
JP2023513208A (ja) * 2020-02-07 2023-03-30 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク 神経変性の発症を遅延させるかまたは神経変性を処置するためのメタボロームのリプログラミング
TW202216158A (zh) * 2020-07-10 2022-05-01 國立研究開發法人理化學研究所 網膜色素上皮細胞之移植用存活促進劑
CN112544612A (zh) * 2020-12-18 2021-03-26 江苏艾尔康生物医药科技有限公司 冻存液及其在rpe细胞冻存中的应用
CN112834411B (zh) * 2021-01-07 2022-05-27 上海交通大学 应用于质谱流式技术的金属纳米探针及制备方法和应用
US20250000788A1 (en) * 2021-01-26 2025-01-02 Sigilon Therapeutics, Inc. Biocompatible devices for cell-based therapies and related methods
CN112926116B (zh) * 2021-03-01 2023-02-17 哈尔滨工业大学 一种基于虚拟现实的体育馆火灾疏散行为数据收集系统及其收集方法
CN114246938A (zh) * 2022-01-25 2022-03-29 中山大学中山眼科中心 Il-4在制备用于治疗视网膜变性疾病药物中的应用
WO2023149420A1 (ja) * 2022-02-01 2023-08-10 株式会社坪田ラボ 近視を予防または治療するための方法および組成物
CN114561356B (zh) * 2022-03-09 2022-09-13 北京呈诺医学科技有限公司 影响细胞因子分泌的方法及应用
CA3254454A1 (en) * 2022-03-16 2025-03-04 Racthera Co., Ltd. METHOD OF TRANSPLANTATION
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
WO2024218311A1 (fr) * 2023-04-21 2024-10-24 Pulsesight Therapeutics Compositions à base de décorine pour la réparation et la régéneration de l'épithélium pigmentaire de la rétine
AU2024268057A1 (en) * 2023-05-05 2025-12-04 The Regents Of The University Of California Retinal pigment epithelium cell therapy
CN117625536B (zh) * 2024-01-26 2024-04-30 中国人民解放军总医院第三医学中心 一种人视网膜色素上皮细胞的纯化、培养方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138205A (en) 1975-12-15 1979-02-06 Hydro Pulse Corporation Movable stator walls permitting access to tubing in peristaltic pump
US5610753A (en) 1991-12-12 1997-03-11 Eastman Kodak Company Optical design of laser scanner to reduce thermal sensitivity
GB9608145D0 (en) * 1996-04-19 1996-06-26 British Tech Group Wound healing
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
US5998423A (en) 1996-10-08 1999-12-07 Therasys, Inc. Methods for modulating melanin production
US6440933B1 (en) 1997-09-10 2002-08-27 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
JP2002500202A (ja) * 1998-01-02 2002-01-08 タイタン ファーマシューティカルズ， インコーポレイテッド 免疫優位部位の生成のための色素性網膜上皮細胞の使用
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
AU2002236495B2 (en) 2000-11-29 2006-05-11 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
WO2002087530A1 (en) * 2001-04-27 2002-11-07 The General Hospital Corporation Tyrosinase assay
JP2004538005A (ja) * 2001-08-08 2004-12-24 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア シアル酸に結合するタンパク質を有するウイルスベクターの精製法
US20030232430A1 (en) 2001-11-26 2003-12-18 Advanced Cell Technology Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
AU2003235652A1 (en) 2002-01-15 2003-07-30 Advanced Cell Technology, Inc. Cloning b and t lymphocytes
US20040091936A1 (en) 2002-05-24 2004-05-13 Michael West Bank of stem cells for producing cells for transplantation having HLA antigens matching those of transplant recipients, and methods for making and using such a stem cell bank
US7803750B2 (en) 2002-07-29 2010-09-28 Duke University Method of modulating melanin production
BRPI0507074A (pt) * 2004-01-23 2007-06-19 Advanced Cell Tech Inc modalidades aperfeiçoadas para o tratamento de doenças degenerativas da retina
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US7309487B2 (en) * 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
ZA200901914B (en) * 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
IL292561A (en) * 2007-10-12 2022-06-01 Astellas Inst For Regenerative Medicine Improved methods of rpe cell production and rpe cell preparations
GB0806746D0 (en) 2008-04-14 2008-05-14 Ucl Business Plc Membrane
WO2009129497A2 (en) * 2008-04-18 2009-10-22 Arizona Board Of Regents, A Body Corp. Of The State Of Arizona, Acting For And On Behalf Of The University Of Arizona Methods and compositions for treating and identifying compounds to treat age-related macular degeneration
US10485829B2 (en) * 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
EP2596119B8 (en) * 2010-07-23 2021-06-02 Astellas Institute for Regenerative Medicine Methods for detection of rare subpopulations of cells and highly purified compositions of cells
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
JP6185907B2 (ja) 2011-03-30 2017-08-23 セルラー ダイナミクス インターナショナル， インコーポレイテッド 神経分化のための多能性幹細胞の予備刺激
WO2012149484A2 (en) * 2011-04-29 2012-11-01 University Of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
TWI719277B (zh) * 2011-11-14 2021-02-21 美商安斯泰來再生醫藥協會 人類rpe細胞之醫藥組合物及其用途
WO2016037159A1 (en) * 2014-09-05 2016-03-10 Ocata Therapeutics, Inc. Retinal ganglion cells and progenitors thereof

Also Published As

Publication number Publication date
HUE044778T2 (hu) 2019-11-28
JP2024037864A (ja) 2024-03-19
AU2017225146C1 (en) 2019-08-22
FI2780022T4 (fi) 2023-07-06
GB201220511D0 (en) 2012-12-26
HRP20191110T1 (hr) 2019-09-20
DK2780022T3 (da) 2019-07-15
HK1202456A1 (en) 2015-10-02
AU2019201201A1 (en) 2019-03-14
PT2780022T (pt) 2019-07-16
ES2734453T3 (es) 2019-12-10
KR20140096368A (ko) 2014-08-05
JP2021113193A (ja) 2021-08-05
EP2780022A4 (en) 2015-08-05
TWI842079B (zh) 2024-05-11
IL287381A (en) 2021-12-01
IL232600A0 (en) 2014-06-30
RS59050B1 (sr) 2019-08-30
AU2025201277A1 (en) 2025-03-13
IL320536A (en) 2025-06-01
JP2025161815A (ja) 2025-10-24
KR102054904B1 (ko) 2019-12-11
EP2780022B2 (en) 2022-09-07
JP7081016B2 (ja) 2022-06-06
JP6563996B2 (ja) 2019-08-21
IL308205B1 (en) 2025-06-01
JP7716463B2 (ja) 2025-07-31
CN104080464A (zh) 2014-10-01
JP7404441B2 (ja) 2023-12-25
WO2013074681A1 (en) 2013-05-23
IL308205A (en) 2024-01-01
TWI719277B (zh) 2021-02-21
SI2780022T1 (sl) 2019-09-30
TWI655286B (zh) 2019-04-01
AU2012340020A1 (en) 2014-07-03
AU2021204719B2 (en) 2024-11-21
US20150366915A1 (en) 2015-12-24
LT2780022T (lt) 2019-07-10
JP2014533289A (ja) 2014-12-11
CY1121819T1 (el) 2020-07-31
IL273107A (en) 2020-04-30
AU2019201201B2 (en) 2021-04-08
TW201333200A (zh) 2013-08-16
IL273107B (en) 2021-12-01
IL287381B2 (en) 2024-04-01
AU2021204719A1 (en) 2021-08-05
AU2017225146B2 (en) 2019-01-17
CN113786417A (zh) 2021-12-14
TW202317157A (zh) 2023-05-01
WO2013074681A9 (en) 2013-11-28
US20130195806A1 (en) 2013-08-01
US20250134932A1 (en) 2025-05-01
DK2780022T4 (da) 2024-09-09
JP2018048144A (ja) 2018-03-29
TWI785403B (zh) 2022-12-01
JP2022130370A (ja) 2022-09-06
US20200405767A1 (en) 2020-12-31
IL232600B (en) 2020-03-31
CA3178098A1 (en) 2013-05-23
AU2017225146A1 (en) 2017-10-05
GB2496969A (en) 2013-05-29
TW202120107A (zh) 2021-06-01
JP2019189614A (ja) 2019-10-31
JP6506023B2 (ja) 2019-04-24
EP3563860A1 (en) 2019-11-06
JP6899865B2 (ja) 2021-07-07
PL2780022T3 (pl) 2019-11-29
IL287381B1 (en) 2023-12-01
IL308205B2 (en) 2025-10-01
TW202434266A (zh) 2024-09-01
EP2780022B1 (en) 2019-06-05
TW201828960A (zh) 2018-08-16
EP2780022A1 (en) 2014-09-24

Similar Documents

Publication Publication Date Title
AU2021204719B2 (en) Pharmaceutical preparations of human RPE cells and uses thereof
HK40015631A (en) Pharmaceutical preparations of human rpe cells and uses thereof
HK40064545A (en) Pharmaceutical preparations of human rpe cells and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171030

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241108

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241108

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241108

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250303

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250303

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250304

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20250626

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250626

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250630

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250804

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20250804

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250804

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250804

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250804

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250804

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251107

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107